From Surgical Boundaries to Oncological Benefit: Integrated Selection in High-Complexity Abdominal Malignancies
DOI:
https://doi.org/10.64784/299Palabras clave:
abdominal tumors, resectability, advanced imaging, tumor biology, surgical oncology, conversion therapy, vascular reconstruction, multivisceral resection, multidisciplinary assessment, functional reserveResumen
Resectability in complex abdominal tumors has evolved from a predominantly anatomical concept into a dynamic assessment that integrates imaging, tumor biology, functional reserve, treatment response, and surgical capability. This study analyzed the principal criteria used to determine resectability in pancreatic tumors, primary hepatic malignancies, colorectal liver metastases, gastric and peritoneal tumors, and retroperitoneal sarcomas. A descriptive and analytical integrative review of 20 scientific publications was conducted using a structured scientific-method framework. Surgical strategy was addressed in 85% of the publications, tumor biology in 80%, advanced imaging in 75%, treatment response in 55%, and patient functional reserve in 45%. Contrast-enhanced computed tomography was the most frequently reported imaging modality, followed by magnetic resonance imaging, PET/CT, functional or volumetric imaging, and radiomics. Metastatic distribution and progression pattern were the most frequently incorporated biological factors, followed by histological subtype, tumor grade, response to systemic treatment, tumor-marker dynamics, and molecular alterations. Vascular resection and reconstruction represented the most frequently reported strategy for expanding resectability, followed by combined resection and ablation, multivisceral resection, staged procedures, future liver remnant augmentation, and transplantation. The findings demonstrate that anatomical removability alone is insufficient to define surgical eligibility. Resectability should be classified as immediately resectable, borderline resectable, potentially convertible, technically unresectable, biologically unresectable, or physiologically unresectable. Multidisciplinary reassessment is essential because the initial classification may change after systemic treatment, functional optimization, or advanced surgical planning. The final objective is to identify patients in whom complete local treatment can be achieved with acceptable morbidity, preserved function, and a reasonable probability of durable oncological benefit.
Referencias
• Al-Hawary, M. M., Francis, I. R., Chari, S. T., Fishman, E. K., Hough, D. M., Lu, D. S., Macari, M., Megibow, A. J., Miller, F. H., Mortele, K. J., Merchant, N. B., Minter, R. M., Tamm, E. P., Sahani, D. V., & Simeone, D. M. (2014). Pancreatic ductal adenocarcinoma radiology reporting template: Consensus statement of the Society of Abdominal Radiology and the American Pancreatic Association. Gastroenterology, 146(1), 291–304.e1. https://doi.org/10.1053/j.gastro.2013.11.004
• Bockhorn, M., Uzunoglu, F. G., Adham, M., Imrie, C., Milicevic, M., Sandberg, A. A., Asbun, H. J., Bassi, C., Büchler, M., Charnley, R. M., Conlon, K., Dervenis, C., Fingerhut, A., Friess, H., Gouma, D. J., Hartwig, W., Lillemoe, K. D., Montorsi, M., Neoptolemos, J. P., … International Study Group of Pancreatic Surgery. (2014). Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery. Surgery, 155(6), 977–988. https://doi.org/10.1016/j.surg.2014.02.001
• Bonney, G. K., Chew, C. A., Lodge, P., Hubbard, J., Halazun, K. J., Trunečka, P., Muiesan, P., Mirza, D. F., Isaac, J., Laing, R. W., McKeown, D., Butler, A. J., Watson, C. J. E., Pratschke, J., Pascher, A., Jassem, W., Heaton, N., Schemmer, P., Oldhafer, K. J., … Hagness, M. (2021). Liver transplantation for non-resectable colorectal liver metastases: The International Hepato-Pancreato-Biliary Association consensus guidelines. The Lancet Gastroenterology & Hepatology, 6(11), 933–946. https://doi.org/10.1016/S2468-1253(21)00219-3
• Charnsangavej, C., Clary, B., Fong, Y., Grothey, A., Pawlik, T. M., & Choti, M. A. (2006). Selection of patients for resection of hepatic colorectal metastases: Expert consensus statement. Annals of Surgical Oncology, 13(10), 1261–1268. https://doi.org/10.1245/s10434-006-9023-y
• Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., Kaplan, R., Lacombe, D., & Verweij, J. (2009). New response evaluation criteria in solid tumours: Revised RECIST guideline, version 1.1. European Journal of Cancer, 45(2), 228–247. https://doi.org/10.1016/j.ejca.2008.10.026
• Folprecht, G., Gruenberger, T., Bechstein, W. O., Raab, H. R., Lordick, F., Hartmann, J. T., Lang, H., Frilling, A., Stoehlmacher, J., Weitz, J., Konopke, R., Stroszczynski, C., Liersch, T., Ockert, D., Herrmann, T., Goekkurt, E., Parisi, F., Köhne, C. H., & Stintzing, S. (2010). Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. The Lancet Oncology, 11(1), 38–47. https://doi.org/10.1016/S1470-2045(09)70330-4
• Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999). Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: Analysis of 1,001 consecutive cases. Annals of Surgery, 230(3), 309–321. https://doi.org/10.1097/00000658-199909000-00004
• Gillies, R. J., Kinahan, P. E., & Hricak, H. (2016). Radiomics: Images are more than pictures, they are data. Radiology, 278(2), 563–577. https://doi.org/10.1148/radiol.2015151169
• Götze, T. O., Piso, P., Lorenzen, S., Bankstahl, U. S., Pauligk, C., Elshafei, M., Amato, G., Reim, D., Bechstein, W. O., & Al-Batran, S. E. (2019). Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III PREVENT trial. BMC Cancer, 19, Article 1158. https://doi.org/10.1186/s12885-019-6128-4
• Huiskens, J., Bolhuis, K., Engelbrecht, M. R. W., De Jong, K. P., Kazemier, G., Liem, M. S. L., Verhoef, C., de Wilt, J. H. W., Punt, C. J. A., & Swijnenburg, R. J. (2019). Outcomes of resectability assessment of the Dutch Colorectal Cancer Group liver metastases expert panel. Journal of the American College of Surgeons, 229(6), 523–532. https://doi.org/10.1016/j.jamcollsurg.2019.08.1445
• Kulkarni, N. M., Soloff, E. V., Tolat, P. P., Chatterjee, A., Thomas, S., Katabathina, V. S., Hough, D. M., Gage, K. L., Zaheer, A., Al-Hawary, M. M., & Tamm, E. P. (2020). White paper on pancreatic ductal adenocarcinoma from Society of Abdominal Radiology’s Disease-Focused Panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease. Abdominal Radiology, 45(3), 716–728. https://doi.org/10.1007/s00261-019-02289-5
• Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., van Wijk, Y., Woodruff, H., van Soest, J., Lustberg, T., Roelofs, E., van Elmpt, W., Dekker, A., Mottaghy, F. M., Wildberger, J. E., & Walsh, S. (2017). Radiomics: The bridge between medical imaging and personalized medicine. Nature Reviews Clinical Oncology, 14(12), 749–762. https://doi.org/10.1038/nrclinonc.2017.141
• Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., Camerini, T., Roayaie, S., Schwartz, M. E., Grazi, G. L., Adam, R., Neuhaus, P., Salizzoni, M., Bruix, J., Forner, A., De Carlis, L., Cillo, U., Burroughs, A. K., Troisi, R., … Metroticket Investigator Study Group. (2009). Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. The Lancet Oncology, 10(1), 35–43. https://doi.org/10.1016/S1470-2045(08)70284-5
• Nieuwenhuizen, S., Puijk, R. S., van den Bemd, B. A. T., Aldrighetti, L., Arntz, M., van den Boezem, P. B., Bruynzeel, A. M. E., Burgmans, M. C., de Cobelli, F., Coolsen, M. M. E., Dejong, C. H. C., de Jong, K. P., Dijkstra, M., van Duijvendijk, P., Eker, H. H., van Etten, B., Grünhagen, D. J., Hartgrink, H. H., van der Heide, U. A., … Meijerink, M. R. (2020). Resectability and ablatability criteria for the treatment of liver-only colorectal metastases: Multidisciplinary consensus document from the COLLISION Trial Group. Cancers, 12(7), Article 1779. https://doi.org/10.3390/cancers12071779
• Park, J. H., Kim, T. Y., Lee, K. H., Han, S. W., Oh, D. Y., Im, S. A., Bang, Y. J., Chie, E. K., Ha, S. W., & Jeong, S. Y. (2014). The beneficial effect of palliative resection in metastatic colorectal cancer. British Journal of Cancer, 110(6), 1425–1431. https://doi.org/10.1038/bjc.2014.74
• Pawlik, T. M., Scoggins, C. R., Zorzi, D., Abdalla, E. K., Andres, A., Eng, C., Curley, S. A., Loyer, E. M., Muratore, A., Mentha, G., Capussotti, L., & Vauthey, J. N. (2005). Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Annals of Surgery, 241(5), 715–724. https://doi.org/10.1097/01.sla.0000160703.75808.7d
• Raut, C. P., Callegaro, D., Miceli, R., Barretta, F., Rutkowski, P., Blay, J. Y., Lahat, G., Strauss, D. C., Gonzalez, R., Ahuja, N., van Coevorden, F., Fairweather, M., Hayes, A. J., Grignani, G., Fiore, M., Mussi, C., Casali, P. G., Bonvalot, S., Gronchi, A., & Transatlantic Australasian Retroperitoneal Sarcoma Working Group. (2019). Predicting survival in patients undergoing resection for locally recurrent retroperitoneal sarcoma: A study and novel nomogram from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Journal of Clinical Oncology, 37(18), 1569–1578. https://doi.org/10.1200/JCO.18.02116
• Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., Salem, R., Sangro, B., Singal, A. G., Vogel, A., Fuster, J., Ayuso, C., & Bruix, J. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology, 76(3), 681–693. https://doi.org/10.1016/j.jhep.2021.11.018
• Swallow, C. J., Strauss, D. C., Bonvalot, S., Rutkowski, P., Desai, A., Gladdy, R. A., Gonzalez, R., Gyorki, D. E., Fairweather, M., van Houdt, W. J., Gronchi, A., & Transatlantic Australasian Retroperitoneal Sarcoma Working Group. (2021). Management of primary retroperitoneal sarcoma in the adult: An updated consensus approach from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Annals of Surgical Oncology, 28(12), 7873–7888. https://doi.org/10.1245/s10434-021-09654-z
• Vauthey, J. N., Zimmitti, G., Kopetz, S. E., Shindoh, J., Chen, S. S., Andreou, A., Curley, S. A., Aloia, T. A., & Maru, D. M. (2013). RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Annals of Surgery, 258(4), 619–627. https://doi.org/10.1097/SLA.0b013e3182a5025a
